{
    "clinical_study": {
        "@rank": "159714", 
        "acronym": "CARE-Hep C", 
        "arm_group": [
            {
                "arm_group_label": "Hepatitis C Virus (HCV) patients exposed to BMS-986094", 
                "description": "Hepatitis C infected patients with previous exposure to BMS-986094"
            }, 
            {
                "arm_group_label": "HCV patients not exposed to BMS-986094", 
                "description": "Hepatitis C patients without exposure to BMS-986094"
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma, serum, and urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to monitor the cardiovascular and renal health of patients who\n      previously took BMS-986094 (an investigational medication for hepatitis C) in comparison to\n      hepatitis C infected patients who have never taken BMS-986094."
        }, 
        "brief_title": "Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects will be enrolled based on prior enrollment in the BMS 986094 studies or\n        treatment-na\u00efve HCV subjects with no known cardiovascular abnormalities.\n\n          1. All Subjects must give informed consent prior to participation in the study.\n\n          2. Subject participated in the Phase 1 or Phase 2 trials with BMS 986094 (including\n             placebo arm) OR\n\n          3. Subject with known hepatitis C (Control)\n\n               1. No previous exposure to BMS 986094\n\n               2. Treatment naive at study entry (No prior hepatitis C treatment experience at the\n                  time of enrollment, including but not limited to: standard interferon, pegylated\n                  interferon, ribavirin, boceprevir, telaprevir, or other experimental drugs for\n                  hepatitis C).\n\n        Exclusion Criteria\n\n          1. For subjects who participated in the Phase 1 or Phase 2 trials with BMS 986094, there\n             are no exclusion criteria\n\n          2. For the control group of subjects without exposure to BMS 986094, the following\n             exclusion criteria, based on clinically available data, apply:\n\n               1. Signs or symptoms of decompensated liver disease such as variceal bleeding,\n                  ascites, hepatic encephalopathy, active jaundice defined by an indirect\n                  bilirubin >2, ALT or AST laboratory values \u2265 10 times the upper limit of normal,\n                  or other evidence of decompensated liver disease or hepatocellular carcinoma\n\n               2. Chronic liver disease other than HCV not limited to Hepatitis B virus (positive\n                  test for HBsAg), hemochromatosis, auto-immune hepatitis, alcoholic liver disease\n                  or non-alcoholic fatty liver disease\n\n               3. History of liver transplantation\n\n               4. Co-infection with HIV (positive test for anti-HIV Ab)\n\n               5. Prior history of cardiomyopathy (ejection fraction \u2264 50%) or history of heart\n                  failure\n\n               6. Signs or symptoms of decompensated heart failure or\n\n               7. Prior history of coronary artery disease, acute myocardial infarction or\n                  coronary artery revascularization (percutaneous or coronary artery bypass\n                  grafting)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hepatitis C positive subjects previously exposed to BMS 986094 and Hepatitis C positive\n        subjects not previously exposed to BMS 986094."
            }
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846494", 
            "org_study_id": "Pro00042419", 
            "secondary_id": "Pro00044788"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92105"
                    }, 
                    "name": "Tuan Nguyen, MD"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Quest Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Jacob Lalezari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }, 
                    "name": "Kansas City Gastroenterology and Hepatology"
                }, 
                "investigator": {
                    "last_name": "Bradley Freilich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asheville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28801"
                    }, 
                    "name": "Asheville Gastroenterology Associates, PA"
                }, 
                "investigator": {
                    "last_name": "William Harlan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "74104"
                    }, 
                    "name": "Options Health Research"
                }, 
                "investigator": {
                    "last_name": "Harvey Tatum, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Central Texas Clinical Research"
                }, 
                "investigator": {
                    "last_name": "David Wright, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Alamo Medical Research"
                }, 
                "investigator": {
                    "last_name": "Eric Lawitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Fundacion de Investigation de Diego"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)", 
        "overall_contact": {
            "email": "jennifer.murphy@duke.edu", 
            "last_name": "Jennifer Murphy", 
            "phone": "919-668-8795"
        }, 
        "overall_official": {
            "affiliation": "Duke Clinical Research Institute", 
            "last_name": "Adrian F. Hernandez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assess incidence of cardiovascular dysfunction among subjects exposed to BMS-986094  and compare with a similar population of HCV subjects who were not exposed to BMS-986094.", 
                "measure": "Cardiovascular dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Assess incidence of renal dysfunction among subjects exposed to BMS-986094 and compare with a similar population of HCV subjects who were not exposed to BMS-986094.", 
                "measure": "Renal dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "May 2014"
    }
}